STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAMP
  4. [Form 4] Camp4 Therapeutics Corp Insider Trading Activity

Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share, expire on March 31, 2036, and vest in equal monthly installments over four years from the grant date.

Positive

  • None.

Negative

  • None.
Insider Maricich Yuri
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 215,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 215,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Options granted 215,000 options Stock Option (Right to Buy) granted to CMO
Exercise price $4.46 per share Conversion or exercise price of options
Underlying shares 215,000 shares Common stock underlying the options
Post-grant derivative holdings 215,000 options Total options held following transaction
Expiration date March 31, 2036 Option expiration for granted award
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "4.4600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the option vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
underlying security financial
"underlying_security_title: "Common Stock""
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maricich Yuri
(Last)(First)(Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.4604/01/2026A215,000 (1)03/31/2036Common Stock215,000$0215,000D
Explanation of Responses:
1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.
Remarks:
/s/ Josh Mandel-Brehm, as Attorney-in-Fact04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CAMP report for Yuri Maricich on this Form 4?

Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options for 215,000 shares. These options were awarded as a compensation-related grant, not an open-market purchase or sale, and give him the right to buy CAMP common stock at a fixed exercise price.

How many CAMP stock options were granted to Yuri Maricich and at what price?

Yuri Maricich was granted stock options covering 215,000 shares of Camp4 Therapeutics common stock. The options carry an exercise price of $4.46 per share, meaning he can purchase shares at that price once they vest and before the options expire, subject to plan terms.

When do Yuri Maricich’s CAMP stock options vest and expire?

The stock options vest in equal monthly installments over four years starting from the grant date. They have an expiration date of March 31, 2036, giving a long timeframe during which vested options may be exercised, assuming continued service and satisfaction of any plan conditions.

Did the CAMP Form 4 show any open-market buying or selling by Yuri Maricich?

The Form 4 shows a grant of derivative securities, not an open-market trade. The single reported transaction is an option award coded as a grant or other acquisition, so there were no open-market purchases or sales of CAMP common stock in this particular filing.

What is Yuri Maricich’s CAMP option position after this reported grant?

After this transaction, Yuri Maricich is shown holding 215,000 stock options directly. These options relate to 215,000 underlying shares of Camp4 Therapeutics common stock and represent his reported derivative position from this filing, subject to vesting and expiration terms under the grant.